Latest Development Pipeline News

Biotron Limited has successfully closed its fully subscribed rights issue, raising $1.52 million, and completed the acquisition of Sedarex Limited, positioning itself for growth in its diversified biotech portfolio.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Lunnon Metals has secured unconditional status for its Ore Purchase Agreement with Gold Fields and approved mining at Lady Herial, backed by a robust feasibility study projecting strong cash flows. Exploration continues aggressively across its gold and nickel projects in Western Australia.

Micro-X Ltd has secured a historic $3.3 million order for its Rover mobile X-ray units in Malaysia, alongside a $6.2 million capital raise to fuel its expanding medical imaging and security technology pipeline.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Brazilian Rare Earths Limited (BRE) reports a robust scoping study for its Amargosa Bauxite-Gallium Project, alongside a strategic heavy rare earths partnership and a strong cash position to accelerate development.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

St Barbara Limited reports strong feasibility outcomes for its New Simberi Gold Project and Nova Scotia developments, backed by significant strategic investments and regulatory approvals.

Aurum Resources has reported further high-grade gold intercepts at its BMT3 deposit within the Boundiali Gold Project, reinforcing resource confidence ahead of key 2026 milestones. The company is advancing aggressive drilling and development plans backed by a strong cash position.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Tesoro Gold Limited ended December 2025 with a strong cash position of AUD 29.2 million, supporting more than four quarters of exploration and operating activities. The company’s latest cash flow report reveals steady financing inflows amid ongoing investment in its gold exploration projects.